Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16874630 | 0.81 | SIGMAR1 (0.49) | KMT2AMEN1KDM4EMAPK1TP53 | |
| SCHEMBL16892067 | 0.80 | HCRTR1 (0.44) | KMT2AMEN1KDM4EMAPK1TP53 | |
| SCHEMBL16874556 | 0.73 | SIGMAR1 (0.54) | KMT2AMEN1KDM4EMAPK1SIGMAR1 | |
| SCHEMBL16874555 | 0.73 | SIGMAR1 (0.54) | KMT2AMEN1KDM4EMAPK1SIGMAR1 | |
| SCHEMBL16874569 | 0.71 | LMNA (0.46) | KMT2AMEN1KDM4ESIGMAR1HCRTR1 | |
| SCHEMBL16874568 | 0.71 | LMNA (0.46) | KMT2AMEN1KDM4ESIGMAR1HCRTR1 | |
| SCHEMBL7947324 | 0.69 | MEN1 (0.48) | KMT2AMEN1KDM4EMAPK1SIGMAR1 | |
| SCHEMBL29593920 | 0.67 | ALDH1A1 (0.51) | KMT2AMEN1KDM4ESIGMAR1HCRTR1 | |
| SCHEMBL22911243 | 0.67 | ALDH1A1 (0.51) | KMT2AMEN1KDM4ESIGMAR1HCRTR1 | |
| SCHEMBL16874586 | 0.66 | KCNH2 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KMT2A 2824/4885MEN1 4538/4885KDM4E 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.